Clearmind Medicine Patent Targets Binge Disorders
Ticker: CMND · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1892500
Sentiment: neutral
Topics: patent, pharmaceuticals, R&D, healthcare
TL;DR
Clearmind Medicine filed a patent for binge disorder treatment, a potential breakthrough.
AI Summary
Clearmind Medicine Inc. announced on October 20, 2025, the publication of a U.S. patent application. This application targets binge behavior disorders, potentially offering new therapeutic approaches. The company is a foreign private issuer filing a Form 6-K report.
Why It Matters
The publication of this patent application signifies progress in Clearmind Medicine's research and development efforts to address significant behavioral health issues.
Risk Assessment
Risk Level: medium — The company is a foreign private issuer with a focus on pharmaceutical preparations, which carries inherent risks related to drug development and regulatory approval.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the report and subject of the press release.
- October 20, 2025 (date) — Date of the press release and filing.
- 001-41557 (other) — SEC file number for Clearmind Medicine Inc.
- 2834 (other) — Standard Industrial Classification code for Pharmaceutical Preparations.
FAQ
What is the specific nature of the U.S. patent application announced by Clearmind Medicine?
The U.S. patent application targets binge behavior disorders.
When was the press release regarding the patent application issued?
The press release was issued on October 20, 2025.
What form did Clearmind Medicine file with the SEC?
Clearmind Medicine filed a Form 6-K.
What is Clearmind Medicine's Standard Industrial Classification code?
Clearmind Medicine's SIC code is 2834, Pharmaceutical Preparations.
Does Clearmind Medicine file annual reports under Form 20-F or 40-F?
Clearmind Medicine files annual reports under Form 20-F.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2025-10-20 07:45:20
Filing Documents
- ea0261784-6k_clearmind.htm (6-K) — 10KB
- ea026178401ex99-1_clearmind.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-100144.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: October 20, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3